Tirzepatide: What the Clinical Evidence Shows About This Dual Incretin Agonist

What it is

After a meal your gut releases two hormones that tell the pancreas to make insulin and the brain that you are full: GLP-1 and GIP. Semaglutide copies the first. Tirzepatide, made by Eli Lilly, is a 39-amino-acid peptide engineered to activate both receptors, with a fatty chain attached so it rides on a blood protein for about five days. One injection a week.

Lilly sells it as Mounjaro for type 2 diabetes and Zepbound for weight loss and sleep apnea. Like semaglutide, it is one of the few peptides on this site with the full stack of evidence: multiple large Phase III trials, FDA approval, and millions of prescriptions.

What it is studied for

Weight loss and type 2 diabetes, both approved. Obstructive sleep apnea in people with obesity, approved in 2024. A heart-outcomes trial (SURPASS-CVOT) is running.

What the evidence actually shows

In humans

SURMOUNT-1 enrolled 2,539 adults with obesity and no diabetes. After 72 weeks, average weight loss was 15.0% on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg, against 3.1% on placebo. No drug had produced more than 20% before (Jastreboff et al., 2022). In people who also had diabetes (SURMOUNT-2), the top dose produced 14.7% (Garvey et al., 2023).

For diabetes, the SURPASS program cut HbA1c by 1.9 to 2.6 points and brought a large share of participants into the non-diabetic range, which older drugs rarely manage (Rosenstock et al., 2021). Head to head against semaglutide 1 mg in people with diabetes, every tirzepatide dose won on both blood sugar and weight (Frías et al., 2021), and a later trial at full weight-loss doses (SURMOUNT-5) again favored tirzepatide.

SURMOUNT-OSA found large reductions in breathing interruptions in people with obesity and sleep apnea, which earned the third approval. The heart-outcomes trial is not finished; semaglutide’s SELECT result, 20% fewer major heart events, has no tirzepatide equivalent yet.

What happens when you stop

SURMOUNT-4 took people who had lost weight on tirzepatide and switched half to placebo. Those on placebo regained a large share of the lost weight within a year. Same lesson as semaglutide: it manages weight while you take it.

Muscle

Roughly a quarter to a third of the weight lost in the trials was lean mass. Whether resistance training and protein fully offset that is being studied.

How it works

The GLP-1 half does what semaglutide does: slows the stomach, dampens hunger in the brain, boosts insulin when blood sugar is high, and turns down glucagon. The GIP half was the surprise. Mice without a GIP receptor resist obesity, so you might expect activating it to add fat. Instead, pharmacological doses of GIP seem to improve how fat tissue handles insulin and add a second route into the brain’s appetite system, and the two together outperform GLP-1 alone (Samms et al., 2023). The exact mechanism is still being worked out.

How it is used

Weekly injection under the skin of the belly, thigh, or upper arm, starting at 2.5 mg for four weeks, then 5 mg, then up in 2.5 mg steps to a maximum of 15 mg as tolerated. The slow climb is there to keep the stomach side effects manageable; people who go slower often do better. Pens are kept refrigerated.

Side effects and unknowns

Nausea in a quarter to a third of people, plus diarrhea, vomiting, constipation, and reduced appetite, all worst during dose increases. Rare and serious: pancreatitis, gallbladder problems that come with rapid weight loss, a boxed warning about thyroid C-cell tumors from rat studies (anyone with a personal or family history of medullary thyroid cancer should not take it), and low blood sugar if combined with insulin or sulfonylureas. Slowed stomach emptying matters before anesthesia; surgeons ask patients to pause it.

Unknowns: heart outcomes, pending the trial; long-term safety in people who start as adults without diabetes and stay on it for decades; and the muscle question. See the safety guide.

Compounded and “research” tirzepatide

Shortages and a list price around $1,000 a month created a market for compounded and research-vendor versions. The FDA has ended the shortage allowance for mass compounding and warned about products with the wrong dose, the wrong salt form, or no verification of contents. A vial from a research vendor carries none of the trial evidence, because nobody has confirmed what is in it.

How it compares

• Semaglutide: less weight loss (about 15% vs 21%), proven heart protection, longer on the market.
• Tesamorelin: targets deep belly fat through growth hormone; much smaller total effect.
• AOD-9604: a growth hormone fragment whose human trial failed; not comparable.
• See the GLP-1 guide and the fat loss guide.

Legal status

FDA approved: Mounjaro (2022, diabetes), Zepbound (2023, weight management; 2024, sleep apnea). Prescription only, approved in most countries. Not a controlled substance. Not on the WADA Prohibited List.

Bottom line

Tirzepatide produces the largest weight loss of any drug ever tested, beat semaglutide head to head, and has the trial data to prove both. What it lacks, for now, is the heart-outcomes result semaglutide has. The weight returns if you stop, a third of it is muscle on the way down, and the bargain versions are not the drug the trials tested.

References

1. Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. PubMed
2. Frías JP, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. PubMed
3. Rosenstock J, et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. PubMed
4. Garvey WT, et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. PubMed
5. Samms RJ, et al. (2023). How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends Endocrinol Metab. PubMed

See also

• Peptide
  AOD-9604: Research, Mechanism, and What the Evidence Actually Shows

  AOD-9604 is the tail end of the growth hormone molecule, kept for its fat-burning signal and stripped of everything else. Mice lost half their fat on it; a 300-person human trial missed its primary goal.

• Peptide
  Semaglutide: What the Clinical Evidence Shows About This GLP-1 Agonist

  Semaglutide is a lab-made, week-long version of the gut hormone GLP-1, sold as Ozempic, Wegovy, and Rybelsus. It has the largest trials of any peptide on this site: about 15% weight loss over 68 weeks and 20% fewer major heart events.

• Peptide
  Tesamorelin: The FDA-Approved GHRH Analog With Clinical Evidence for Visceral Fat Reduction

  Tesamorelin (Egrifta) is a lab-made version of GHRH, the signal that tells the pituitary to release growth hormone, and the only one with current FDA approval. In Phase III trials it cut deep belly fat by about 18% in people with HIV.